Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

AIMS: Immune checkpoint inhibitor (ICI) therapy has become a viable treatment strategy in bladder cancer. However, treatment responses vary, and improved biomarkers are needed. Crucially, the characteristics of immune cells remain understudied especially in squamous differentiated bladder cancer (sq...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Max, Rose, Michael, Knuechel, Ruth, Loeffler, Chiara, Muti, Hannah, Kather, Jakob Nikolas, Gaisa, Nadine T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890720/
https://www.ncbi.nlm.nih.gov/pubmed/36726072
http://dx.doi.org/10.1186/s12885-023-10576-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890720/
https://www.ncbi.nlm.nih.gov/pubmed/36726072
http://dx.doi.org/10.1186/s12885-023-10576-0

Ejemplares similares